Go to
current issue
-
Tumors of the Urinary System and Male Genital Organs: 2022 World Health Organization Classification and Multidisciplinarity Eur. Urol. (IF 24.267) Pub Date : 2022-08-11 Rodolfo Montironi, Alessia Cimadamore
Abstract not available
-
The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs—Part B: Prostate and Urinary Tract Tumors Eur. Urol. (IF 24.267) Pub Date : 2022-08-11 George J. Netto, Mahul B. Amin, Daniel M. Berney, Eva M. Compérat, Anthony J. Gill, Arndt Hartmann, Santosh Menon, Maria R. Raspollini, Mark A. Rubin, John R. Srigley, Puay Hoon Tan, Satish K. Tickoo, Toyonori Tsuzuki, Samra Turajlic, Ian Cree, Holger Moch
The 2022 World Health Organization (WHO) classification of the urinary and male genital tumors was recently published by the International Agency for Research on Cancer. This fifth edition of the WHO “Blue Book” offers a comprehensive update on the terminology, epidemiology, pathogenesis, histopathology, diagnostic molecular pathology, and prognostic and predictive progress in genitourinary tumors
-
Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer Eur. Urol. (IF 24.267) Pub Date : 2022-08-11 Alberto Gil-Jimenez, Jeroen van Dorp, Alberto Contreras-Sanz, Kristan van der Vos, Daniel J. Vis, Linde Braaf, Annegien Broeks, Ron Kerkhoven, Kim E.M. van Kessel, María José Ribal, Antonio Alcaraz, Lodewyk F.A. Wessels, Roland Seiler, Jonathan L. Wright, Lourdes Mengual, Joost Boormans, Bas W.G. van Rhijn, Peter C. Black, Michiel S. van der Heijden
Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy is recommended for patients with muscle-invasive bladder cancer (MIBC). It has been shown that somatic deleterious mutations in ERCC2, gain-of-function mutations in ERBB2, and alterations in ATM, RB1, and FANCC are correlated with pathological response to NAC in MIBC. The objective of this study was to validate these genomic
-
Predicting the Need for Biopsy to Detect Clinically Significant Prostate Cancer in Patients with a Magnetic Resonance Imaging–detected Prostate Imaging Reporting and Data System/Likert ≥3 Lesion: Development and Multinational External Validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk Score Eur. Urol. (IF 24.267) Pub Date : 2022-08-11 Max Peters, David Eldred-Evans, Piet Kurver, Ugo Giovanni Falagario, Martin J. Connor, Taimur T. Shah, Joost J.C. Verhoeff, Pekka Taimen, Hannu J. Aronen, Juha Knaapila, Ileana Montoya Perez, Otto Ettala, Armando Stabile, Giorgio Gandaglia, Nicola Fossati, Alberto Martini, Vito Cucchiara, Alberto Briganti, Hashim U. Ahmed
Background Although multiparametric magnetic resonance imaging (MRI) has high sensitivity, its lower specificity leads to a high prevalence of false-positive lesions requiring biopsy. Objective To develop and externally validate a scoring system for MRI-detected Prostate Imaging Reporting and Data System (PIRADS)/Likert ≥3 lesions containing clinically significant prostate cancer (csPCa). Design, setting
-
Re: Logan G. Briggs, Chanan Reitblat, Paul A. Bain, et al. Prehabilitation Exercise Before Urologic Cancer Surgery: A Systematic and Interdisciplinary Review. Eur Urol 2022;81:157–67 Eur. Urol. (IF 24.267) Pub Date : 2022-08-10 André Pontes-Silva
Abstract not available
-
Re: Mauro Gacci, Vasileios I. Sakalis, Markos Karavitakis, et al. European Association of Urology Guidelines on Male Urinary Incontinence. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.05.012 Eur. Urol. (IF 24.267) Pub Date : 2022-08-09 Meng Lv, Xufei Luo, Yaolong Chen
Abstract not available
-
Re: Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial Eur. Urol. (IF 24.267) Pub Date : 2022-08-09 Claudia Kesch, Boris A. Hadaschik
Abstract not available
-
Re: Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer: The PANDA Challenge Eur. Urol. (IF 24.267) Pub Date : 2022-08-09 Prokar Dasgupta
Abstract not available
-
Reply to Meny Lv, Xufei Luo, and Yaolong Chen’s Letter to the Editor re: Mauro Gacci, Vasileios I. Sakalis, Markos Karavitakis, et al. European Association of Urology Guidelines on Male Urinary Incontinence. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.05.012 Eur. Urol. (IF 24.267) Pub Date : 2022-08-06 Mauro Gacci, Vasileios I. Sakalis, Markos Karavitakis, Stavros Gravas
Abstract not available
-
Reply to Yuxuan Song, Yiqing Du, and Tao Xu’s Letter to the Editor re: Matthew Mossanen, Filipe L.F. Carvalho, Vinayak Muralidhar, et al. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. Eur Urol 2022;81:466–73 Eur. Urol. (IF 24.267) Pub Date : 2022-08-06 Filipe L.F. Carvalho, Matthew Mossanen, Eliezer M. Van Allen, Kent W. Mouw
Abstract not available
-
Re: Matthew Mossanena, Filipe L.F. Carvalhoa, Vinayak Muralidhar, et al. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. Eur Urol 2022;81:466–73 Eur. Urol. (IF 24.267) Pub Date : 2022-08-06 Yuxuan Song, Yiqing Du, Tao Xu
Abstract not available
-
A Path to Precision Medicine in Prostate Cancer: Learning from “Negative” Trials of Targeted Therapies Eur. Urol. (IF 24.267) Pub Date : 2022-08-06 Tanya B. Dorff, Alicia K. Morgans
Abstract not available
-
Stereotactic Ablative Body Radiotherapy: An Emerging Weapon in the Treatment Armamentarium for Renal Cell Carcinoma or a Potential Avenue for Overtreatment? Eur. Urol. (IF 24.267) Pub Date : 2022-08-06 Diana E. Magee, Jessica Karen Wong, Andres F. Correa
Abstract not available
-
Re: Sarah P. Psutka, Roman Gulati, Michael A.S. Jewett, et al. A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. Eur Urol 2022;81:576–85 Eur. Urol. (IF 24.267) Pub Date : 2022-08-06 Mike Wenzel, Felix K-H. Chun, Andreas Becker
Abstract not available
-
Re: Development and Validation of the Metric-based Assessment of a Robotic Dissection Task on an Avian Model Eur. Urol. (IF 24.267) Pub Date : 2022-08-06 Caroline Jamaer, Anne-Françoise Spinoit
Abstract not available
-
Reply to Andreas Skolarikos’s Words of Wisdom re: Effect of Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients with Bladder Cancer: A Randomized Clinical Trial. Eur Urol. In press Eur. Urol. (IF 24.267) Pub Date : 2022-08-06 James W.F. Catto, Pramit Khetrapal, Gareth Ambler, Norman R. Williams, Chris Brew-Graves, John D. Kelly
Abstract not available
-
We Must Change Our Approach to Racial Disparities in Prostate Cancer Eur. Urol. (IF 24.267) Pub Date : 2022-08-05 Samuel L. Washington
Abstract not available
-
Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN) Eur. Urol. (IF 24.267) Pub Date : 2022-08-05 Ting Martin Ma, Fang-I Chu, Howard Sandler, Felix Y. Feng, Jason A. Efstathiou, Christopher U. Jones, Mack Roach, Seth A. Rosenthal, Thomas Pisansky, Jeff M. Michalski, Michel Bolla, Theo M. de Reijke, Philippe Maingon, Anouk Neven, James Denham, Allison Steigler, David Joseph, Abdenour Nabid, Amar U. Kishan
Context The prognostic importance of local failure after definitive radiotherapy (RT) in National Comprehensive Cancer Network intermediate- and high-risk prostate cancer (PCa) patients remains unclear. Objective To evaluate the prognostic impact of local failure and the kinetics of distant metastasis following RT. Evidence acquisition A pooled analysis was performed on individual patient data of 12
-
Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer Eur. Urol. (IF 24.267) Pub Date : 2022-08-03 Ben-Max de Ruiter, Jons W. van Hattum, Djoeri Lipman, Theo M. de Reijke, R. Jeroen A. van Moorselaar, Erik J. van Gennep, A.H. Maartje Piet, Mila Donker, Tom van der Hulle, Jens Voortman, Jorg R. Oddens, Maarten C.C.M. Hulshof, Adriaan D. Bins
Background Muscle-invasive bladder cancer (MIBC) has a poor prognosis. Chemoradiotherapy (CRT) in selected patients has comparable results to radical cystectomy. Results of neoadjuvant immune checkpoint inhibitors (ICIs) before radical cystectomy are promising. We hypothesize that ICI concurrent to CRT (iCRT) is safe and may improve treatment outcomes. Objective To determine the safety of iCRT for
-
Re: Fragmentation of Stones by Burst Wave Lithotripsy in the First 19 Humans Eur. Urol. (IF 24.267) Pub Date : 2022-08-03 Heiko Yang, Marshall Stoller
Abstract not available
-
Re: Effect of Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients with Bladder Cancer: A Randomized Clinical Trial Eur. Urol. (IF 24.267) Pub Date : 2022-08-03 Andreas Skolarikos
Abstract not available
-
Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer Eur. Urol. (IF 24.267) Pub Date : 2022-07-28 Antoni Vilaseca, Maria J. Ribal
Abstract not available
-
Reply to Paulius Bosas, Gintaras Zaleskis, and Dainius Characiejus’s Letter to the Editor re: Sylvia H.J. Jochems, Josef Fritz, Christel Häggström, Bengt Järvholm, Pär Stattin, Tanja Stocks. Smoking and Risk of Prostate Cancer and Prostate Cancer Death: A Pooled Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.033. Therapeutic Monitoring in Prostate Cancer Should Involve a Cotinine Eur. Urol. (IF 24.267) Pub Date : 2022-07-28 Sylvia H.J. Jochems, Pär Stattin, Tanja Stocks
Abstract not available
-
Re: Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer Eur. Urol. (IF 24.267) Pub Date : 2022-07-27 Michael Leveridge, D. Robert Siemens
Abstract not available
-
Re: Pawel Rajwa, Benjamin Pradere, Giorgio Gandaglia, et al. Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2022;82:82–96 Eur. Urol. (IF 24.267) Pub Date : 2022-07-27 Vedang Murthy, Srinivas Chilukuri, Priyamvada Maitre
Abstract not available
-
Re: Sylvia H.J. Jochems, Josef Fritz, Christel Häggström, Bengt Järvholm, Pär Stattin, Tanja Stocks. Smoking and Risk of Prostate Cancer and Prostate Cancer Death: A Pooled Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.033 Eur. Urol. (IF 24.267) Pub Date : 2022-07-27 Paulius Bosas, Gintaras Zaleskis, Dainius Characiejus
Abstract not available
-
Re: High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Localised Prostate Cancer (DART 01/05): 10-Year Results of a Phase 3 Randomised, Controlled Trial Eur. Urol. (IF 24.267) Pub Date : 2022-07-25 Leonard P. Bokhorst, Berdine L. Heesterman
Abstract not available
-
Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a Prospective Phase 2 Study Eur. Urol. (IF 24.267) Pub Date : 2022-07-22 Giorgio Gandaglia, Elio Mazzone, Armando Stabile, Antony Pellegrino, Vito Cucchiara, Francesco Barletta, Simone Scuderi, Daniele Robesti, Riccardo Leni, Ana Maria Samanes Gajate, Maria Picchio, Luigi Gianolli, Giorgio Brembilla, Francesco De Cobelli, Matthias N. van Oosterom, Fijs W.B. van Leeuwen, Francesco Montorsi, Alberto Briganti
Background Extended pelvic nodal dissection (ePLND) represents the gold standard for nodal staging in prostate cancer (PCa). Prostate-specific membrane antigen (PSMA) radioguided surgery (RGS) could identify lymph node invasion (LNI) during robot-assisted radical prostatectomy (RARP). Objective To report the planned interim analyses of a phase 2 prospective study (NCT04832958) aimed at describing PSMA-RGS
-
The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours Eur. Urol. (IF 24.267) Pub Date : 2022-07-16 Holger Moch, Mahul B. Amin, Daniel M. Berney, Eva M. Compérat, Anthony J. Gill, Arndt Hartmann, Santosh Menon, Maria R. Raspollini, Mark A. Rubin, John R. Srigley, Puay Hoon Tan, Satish K. Tickoo, Toyonori Tsuzuki, Samra Turajlic, Ian Cree, George J. Netto
The fifth edition of the World Health Organization (WHO) classification of urogenital tumours (WHO “Blue Book”), published in 2022, contains significant revisions. This review summarises the most relevant changes for renal, penile, and testicular tumours. In keeping with other volumes in the fifth edition series, the WHO classification of urogenital tumours follows a hierarchical classification and
-
Can We Measure the Academic Impact of Social Media? Eur. Urol. (IF 24.267) Pub Date : 2022-07-15 Juan Gómez Rivas, Jeremy Yuen-Chun Teoh, Giovanni Cacciamani
Abstract not available
-
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma Eur. Urol. (IF 24.267) Pub Date : 2022-07-15 Jens Bedke, Brian I. Rini, Elizabeth R. Plimack, Viktor Stus, Rustem Gafanov, Tom Waddell, Dimitry Nosov, Frederic Pouliot, Denis Soulières, Bohuslav Melichar, Ihor Vynnychenko, Sergio J. Azevedo, Delphine Borchiellini, Raymond S. McDermott, Satoshi Tamada, Allison Martin Nguyen, Shuyan Wan, Rodolfo F. Perini, Thomas Powles
Background In the phase 3 KEYNOTE-426 (NCT02853331) trial, pembrolizumab + axitinib demonstrated improvement in overall survival, progression-free survival, and objective response rate over sunitinib monotherapy for advanced renal cell carcinoma (RCC). Objective To evaluate health-related quality of life (HRQoL) in KEYNOTE-426. Design, setting, and participants A total of 861 patients were randomly
-
The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma Eur. Urol. (IF 24.267) Pub Date : 2022-07-14 Muhammad Ali, Jennifer Mooi, Nathan Lawrentschuk, Rana R. McKay, Raquibul Hannan, Simon S. Lo, William A. Hall, Shankar Siva
Context Stereotactic ablative body radiotherapy (SABR) is an emerging treatment modality for primary and metastatic renal cell carcinoma (RCC). Objective To review and summarise the evidence on the use of SABR in RCC in a narrative review. Evidence acquisition We performed an online search of the PubMed database from January 2000 through December 2021. Studies of SABR/stereotactic radiosurgery (SRS)
-
Application of Improved Robot-assisted Laparoscopic Telesurgery with 5G Technology in Urology Eur. Urol. (IF 24.267) Pub Date : 2022-07-09 Jianmin Li, Xuecheng Yang, Guangdi Chu, Wei Feng, Xuemei Ding, Xulong Yin, Liangjun Zhang, Wei Lv, Lufei Ma, Liguo Sun, Run Feng, Jun Qin, Xuefeng Zhang, Chengyi Gou, Zongyi Yu, Bin Wei, Wei Jiao, Yonghua Wang, Haitao Niu
The demand for telesurgery is rising rapidly, but robust evidence regarding the feasibility of its application in urology is still rare. From March to October 2021, a surgeon-controlled surgical robot in a tertiary hospital in Qingdao was used to remotely conduct robot-assisted laparoscopic radical nephrectomy (RN) in 29 patients located in eight primary hospitals. The median round-trip delay was 26
-
Re: ‘Case of the Month’ from the Specialist Centre for Kidney Cancer, Royal Free London Hospital, UK: 99mTc-sestamibi SPECT-CT to Differentiate Renal Cell Carcinoma from Benign Oncocytoma Eur. Urol. (IF 24.267) Pub Date : 2022-07-09 Riccardo Campi, Alessio Pecoraro, Sergio Serni
Abstract not available
-
Integrating Precision Medicine into the Standard of Care for Male Infertility: What Will it Take? Eur. Urol. (IF 24.267) Pub Date : 2022-07-08 Jason Kunisaki, Aaron Quinlan, Kenneth I. Aston, James Hotaling
Abstract not available
-
-
-
-
-
-
-
-
Re: Sounak Gupta, Christine M. Lohse, Ross Rowsey, et al. Renal Neoplasia in Polycystic Kidney Disease: An Assessment of Tuberous Sclerosis Complex–associated Renal Neoplasia and PKD1/TSC2 Contiguous Gene Deletion Syndrome. Eur Urol 2022;81:229–33 Eur. Urol. (IF 24.267) Pub Date : 2022-07-07 Yang Zhao, Wenda Wang, Yushi Zhang
Abstract not available
-
Reply to Yang Zhao, Wenda Wang, and Yushi Zhang’s Letter to the Editor re: Sounak Gupta, Christine M. Lohse, Ross Rowsey, et al. Renal Neoplasia in Polycystic Kidney Disease: An Assessment of Tuberous Sclerosis Complex–associated Renal Neoplasia and PKD1/TSC2 Contiguous Gene Deletion Syndrome. Eur Urol 2022;81:229–33 Eur. Urol. (IF 24.267) Pub Date : 2022-07-07 Sounak Gupta, Christine M. Lohse, Rafael E. Jimenez, John C. Cheville
Abstract not available
-
Aberrant Splice Variants: A Novel Characterization of Clear Cell Renal Cell Carcinoma Eur. Urol. (IF 24.267) Pub Date : 2022-07-05 Jozefina Casuscelli, Sumanta K. Pal
Abstract not available
-
Re: Ekaterina Laukhtina, Shahrokh F. Shariat. Phase II Study of Gemcitabine and Split-dose Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.04.010 Eur. Urol. (IF 24.267) Pub Date : 2022-07-02 Takeshi Takahashi
Abstract not available
-
Re: Chemoradiotherapy in Muscle-invasive Bladder Cancer (BC2001): 10-year Follow-up of a Phase 3 Randomised Controlled Trial Eur. Urol. (IF 24.267) Pub Date : 2022-07-02 Sola Adeleke, Boris Tocco, Veeru Kasivisvanathan
Abstract not available
-
18F-PSMA-11 as an Attractive 68Ga-PSMA-11 Alternative for Prostate Cancer Imaging Eur. Urol. (IF 24.267) Pub Date : 2022-07-02 Pim J. van Leeuwen, Louise Emmett
Abstract not available
-
Re: Lymph Node Colonization Induces Tumor-immune Tolerance To Promote Distant Metastasis Eur. Urol. (IF 24.267) Pub Date : 2022-07-01 Melanie R. Hassler, Shahrokh F. Shariat
Abstract not available
-
Re: Effect of a Smoking and Alcohol Cessation Intervention Initiated Shortly Before Radical Cystectomy—the STOP-OP Study: A Randomised Clinical Trial Eur. Urol. (IF 24.267) Pub Date : 2022-06-30 Andres Affentranger, Richard S. Matulewicz, Christian D. Fankhauser
Abstract not available
-
Re: Clinical Validation of a Targeted Methylation-based Multi-cancer Early Detection Test Using an Independent Validation Set Eur. Urol. (IF 24.267) Pub Date : 2022-06-30 Sabrina H. Rossi, Grant D. Stewart
Abstract not available
-
Time to Rethink Quality of Life Assessment in Patients with Urothelial Cancer in the Current Therapeutic Era? Eur. Urol. (IF 24.267) Pub Date : 2022-06-30 Cristiane Decat Bergerot, Shilpa Gupta
Abstract not available
-
Reply to Yongbao Wei, Ruochen Zhang, and Le Lin’s Letter to the Editor re: Börje Ljungberg, Laurence Albiges, Yasmin Abu-Ghanem, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.006 Eur. Urol. (IF 24.267) Pub Date : 2022-06-27 Börje Ljungberg, Jens Bedke, Umberto Capitanio, Axel Bex
Abstract not available
-
Sperm Retrieval: Who Does It Best? Eur. Urol. (IF 24.267) Pub Date : 2022-06-25 Pippa Sangster
Abstract not available
-
Re: The Impact of COVID-19 Vaccine on Sperm Quality, Barda S, Laskov I, Grisaru D, et al Int J Gynaecol Obstet. In press. https://doi.org/10.1002/ijgo.14135 Eur. Urol. (IF 24.267) Pub Date : 2022-06-24 Walter D. Cardona Maya, Temidayo S. Omolaoye, Stefan S. du Plessis
Abstract not available
-
Bempegaldesleukin/Nivolumab and Challenges in First-line Treatment of Metastatic Urothelial Carcinoma Eur. Urol. (IF 24.267) Pub Date : 2022-06-23 Benjamin Miron, Daniel M. Geynisman
Abstract not available
-
Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1 Eur. Urol. (IF 24.267) Pub Date : 2022-06-22 Fred Saad, Johann de Bono, Philippe Barthélémy, Tanya Dorff, Niven Mehra, Giorgio Scagliotti, Adam Stirling, Jean-Pascal Machiels, Vincent Renard, Marco Maruzzo, Celestia S. Higano, Howard Gurney, Cynthia Healy, Helen Bhattacharyya, Bhakti Arondekar, Alexander Niyazov, Karim Fizazi
Background Talazoparib has shown antitumor activity with a manageable safety profile in men with metastatic castration-resistant prostate cancer (mCRPC) and DNA damage response (DDR)/homologous recombination repair (HRR) alterations. Objective To evaluate patient-reported health-related quality of life (HRQoL) and pain in patients who received talazoparib in the TALAPRO-1 study, with a special interest
-
Re: Börje Ljungberg, Laurence Albiges, Yasmin Abu-Ghanem, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.006 Eur. Urol. (IF 24.267) Pub Date : 2022-06-22 Yongbao Wei, Ruochen Zhang, Le Lin
Abstract not available
-
Robotic Radical Prostatectomy for Prostate Cancer in Renal Transplant Recipients: Results from a Multicenter Series Eur. Urol. (IF 24.267) Pub Date : 2022-06-22 Giancarlo Marra, Marco Agnello, Andrea Giordano, Francesco Soria, Marco Oderda, Charles Dariane, Marc-Olivier Timsit, Julien Brancherau, Oussama Hedli, Benoit Mesnard, Derya Tilki, Jonathon Olsburgh, Meghana Kulkarni, Veeru Kasivisvanathan, Alberto Breda, Luigi Biancone, Paolo Gontero
Background Despite an expected increase in prostate cancer (PCa) incidence in the renal transplant recipient (RTR) population in the near future, robot-assisted radical prostatectomy (RARP) in these patients has been poorly detailed. It is not well understood whether results are comparable to RARP in the non-RTR setting. Objective To describe the surgical technique for RARP in RTR and report results
-
Re: Benjamin Pradere, Richard Mallet, Alexandre de La Taille, et al. Climate-smart Actions in the Operating Theatre for Improving Sustainability Practices: A Systematic Review. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.01.027 Eur. Urol. (IF 24.267) Pub Date : 2022-06-21 Michael Baboudjian, Pietro Diana, Alberto Breda
Abstract not available
更新日期：2022-08-05
Copyright © 2014-2022 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495-2号
京公网安备 11010802027423号
京公网安备 11010802027423号